<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 5)
ALLTRISTA CORPORATION
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, no par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
020040101
--------------------------------------------------------------------------------
(CUSIP Number of Class of Securities)
Marlin Partners II, L.P.
Attn: Martin E. Franklin
555 Theodore Fremd Avenue,
Suite B-302,
Rye, NY 10580
(914)967-9400
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Copies to:
William J. Grant, Esq.
Willkie Farr & Gallagher
787 Seventh Avenue
New York, NY 10019
(212) 728-8000
October 10, 2000
--------------------------------------------------------------------------------
(Date of Event which Requires
Filing of this Schedule)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following: [ ]
<PAGE>
SCHEDULE 13D
------------------- -----------------
CUSIP No. 020040101 Page 2 of 5 Pages
------------------- -----------------
----------- --------------------------------------------------------------------
1 NAME OF REPORT PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Marlin Partners II, L.P.
----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
----------- --------------------------------------------------------------------
3 SEC USE ONLY
----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
----------- -------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
575,700
--------- ------------------------------------------------
8 SHARED VOTING POWER
NUMBER OF
SHARES 0
BENEFICIALLY
OWNED BY --------- ------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH 575,700
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
575,700
----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.13%
----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
----------- --------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
2 of 5
<PAGE>
This Amendment No. 5 to Schedule 13D is being filed by the Reporting Person
solely to report a change in the purpose for which the Reporting Person holds
shares of Common Stock (as defined herein), and is being filed pursuant to Rule
13d-2 under the Securities and Exchange Act of 1934, as amended. There has been
no change in the number of shares of Common Stock held by the Reporting Person
since the filing of Amendment No. 4 to the Schedule 13D, dated August 15, 2000.
Capitalized terms used herein and not otherwise defined herein shall have the
meanings given to them in the Initial Statement. The Initial Statement is
supplementally amended as set forth herein.
Item 1. Security and Issuer.
This Amendment No. 5 to Schedule 13D relates to shares of Common Stock, no
par value (the "Common Stock"), of Alltrista Corporation, an Indiana corporation
(the "Company"). This Amendment No. 5 amends the initial statement (the "Initial
Statement") on Schedule 13D dated January 5, 2000, as amended. The principal
executive offices of the Company are located in 5875 Castle Creek Parkway, North
Drive, Suite 440, Indianapolis, Indiana 46250.
Item 4. Interest in Securities of the Issuer.
Item 4 of the Schedule 13D is amended by adding the following paragraphs to
the end of such item:
3 of 5
<PAGE>
By letter dated October 10, 2000, Mr. Franklin requested Thomas Clark,
President of the Company, to (i) respond to questions outlined in Exhibits A, B
and C to this Schedule 13D, (ii) explain what strategic options are being
reviewed by the Board, (iii) invite a representative of the Reporting Person
(second largest shareholder of the Company) to join the Board of the Company,
and (iv) rescind or amend the Company's "poison pill". A copy of the letter
setting forth the Reporting Person's requests is filed as Exhibit D to this
Schedule 13D.
Item 7. Material to be Filed as Exhibits.
Item 7 of Schedule 13D is hereby amended by adding the following paragraph
to the end of such item:
EXHIBIT D Letter, dated October 10, 2000.
4 of 5
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, the
undersigned certifies that the information set forth in this statement is true,
complete and correct.
Dated: October 10, 2000 MARLIN PARTNERS II, L.P.
By: Marlin Management, L.L.C.,
its General Partner
By: /s/ Martin E. Franklin
------------------------------
Name: Martin E. Franklin
Title: Managing Member
5 of 5
